Heart failure in women: epidemiology, biology and treatment.

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Women s Health 10/2009; 5(5):517-27. DOI: 10.2217/whe.09.50
Source: PubMed

ABSTRACT Although women account for a significant proportion of the growing heart failure epidemic, they have been poorly represented in clinical trials. As emerging epidemiologic data reveal a growing prevalence and burden of disease among women, it is increasingly important that treating physicians and researchers recognize sex-based differences. Despite the overall incidence of heart failure being lower in women compared with men, the magnitude of improvement in survival over the last several decades has been less apparent in women. Women with heart failure are more likely to be older, have preserved systolic function and nonischemic cardiomyopathy. While clinical trials have demonstrated improved outcomes among heart failure patients, they have predominantly included men, yielding results that are sometimes inadequately powered to detect a benefit for women. Without adequate representation of women in clinical trials, one cannot assume that the same level of therapeutic evidence also applies to women. Nonetheless, it appears that beta-blockers and angiotensin-converting enzyme inhibitors provide the same survival benefits in women with systolic dysfunction as in men. In addition, some studies suggest that angiotensin-receptor blockers may lead to a better survival in women when compared with angiotensin-converting enzyme inhibitors. Focused research is needed to understand and guide the management of women with heart failure.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Growing evidence indicates that women with a history of common pregnancy complications, including fetal growth restriction and preterm delivery (often combined as low birth weight), hypertensive disorders of pregnancy, and gestational diabetes, are at increased risk for cardiovascular disease later in life. The purpose of this paper was to review the associations of parity and these 4 pregnancy complications with cardiovascular morbidity and mortality; to review the role of cardiovascular risk factors before, during, and after pregnancy complications in explaining these associations; and to explore the implications of this emerging science for new research and policy. We systematically searched for relevant cohort and case-control studies in Medline through December 2012 and used citation searches for already published reviews to identify new studies. The findings of this review suggest consistent and often strong associations of pregnancy complications with latent and future cardiovascular disease. Many pregnancy complications appear to be preceded by subclinical vascular and metabolic dysfunction, suggesting that the complications may be useful markers of latent high-risk cardiovascular trajectories. With further replication research, these findings would support the utility of these prevalent pregnancy complications in identifying high-risk women for screening, prevention, and treatment of cardiovascular disease, the leading cause of morbidity and mortality among women.
    Epidemiologic Reviews 09/2013; DOI:10.1093/epirev/mxt006 · 7.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Heart disease is a leading cause of morbidity and mortality in both men and women. Our understanding of heart disease stems chiefly from clinical trials on men, but key features of the disease differ in women. This paper reports findings from the first Canadian national survey of women that focuses on knowledge, perceptions and lifestyle related to heart health. Methods A cross-country survey using an adaptation of an instrument used in the United States was undertaken in spring of 2013. Based on online (208) and telephone (1446) responses from a randomly selected sample of women aged 25 or older, a total sample of 1,654 weighted percentage estimates were produced. The overall response rate was 12.5%. Results Just under half of women were able to name smoking as a risk factor of heart disease, and less than one-quarter named hypertension or high cholesterol. Fewer than half of women knew the major symptoms of heart disease. The majority of women prefer to receive information on heart health from their doctor, but only slightly more than half report that their doctor includes discussion of prevention and lifestyle during clinical consultations. Conclusions The majority of women lack knowledge of heart disease symptoms and risk factors, and significant proportions are unaware of their own risk status. The findings underscore the opportunity for patient education and intervention regarding risk and prevention of heart disease.
    The Canadian journal of cardiology 07/2014; 30(7). DOI:10.1016/j.cjca.2014.05.007 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Comparative effectiveness research is a key component to improving heart failure management. Many patients in clinical practice are dissimilar to the patients in randomized controlled trials, so alternative sources of information must guide treatment. There is reasonable evidence to support the use of most heart failure therapeutics in women but less evidence to support use in elderly patients and patients with kidney disease. Safety issues are of particular concern in these special populations.
    Heart Failure Clinics 01/2013; 9(1):79-92. DOI:10.1016/j.hfc.2012.09.003 · 1.41 Impact Factor